Tanya Dorff, MD Genitourinary Cancers:Evolving Practices and Controversies @MOASC_Office @cityofhope

Tanya Dorff, MD Genitourinary Cancers: Evolving Practices and Controversies @MOASC_Office @cityofhope


3 months
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Tanya Dorff, MD Associate Clinical Professor of MedicineHead of Genitourinary Cancer Program City of Hope discusses Genitourinary Cancers:Evolving Practices and Controversies, STAMPEDE: (Docetaxel) in mHSPC, LATITUDE Trial, docetaxel, ENZAMET, SWOG S1802, TITAN, mCRPC, Cabazitaxel, Enzalutamide, Radium223, Sipuleucel-T, Docetaxel (TAX), ADT, A031201, EORTC 1333 / PEACE III2, PARP inhibitors, TOPARP- B, niraparib, rucaparib, talazoparib, PHASE III PROFOUND, Pembrolizumab, KEYNOTE-991, 177-Lu PSMA, VISION trial, CAR-T, BiTE antibody, Erdafitinib, FGFR TKI, Enfortumab, EV 302, Docetaxel, Vofatamab, nivoluamb and more at the MOASC Summit 2020
Up Next Autoplay